Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Shearer

Showing results (401-410 of 531) with videos related to

Pageof 54
Sort By:
The Journal of Infectious Diseases|February 1, 1996
Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelopeA Beretta, S H Weiss, G Rappocciolo, et al.
The Journal of Infectious Diseases|August 1, 1994
Demonstration of human T lymphotropic virus type I (HTLV-I)-specific T cell responses from seronegative and polymerase chain reaction-negative persons exposed to HTLV-IM Nishimura, A G Kermode, M Clerici, et al.
Infection Control and Hospital Epidemiology|July 8, 1999
Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workersR D'Amico, L A Pinto, P Meyer, et al.
The Journal of Clinical Investigation|April 1, 1989
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individualsH Golding, G M Shearer, K Hillman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 1994
Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesisM Clerici, A Sarin, R L Coffman, et al.
AIDS (London, England)|January 6, 1999
Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatmentC Chougnet, K R Fowke, B U Mueller, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pulmonary fibroblast activation during <i>Aspergillus fumigatus</i> infection enhances lung defense via immunomodulation and tissue remodelingJosé P Guirao-Abad, Shannon M Shearer, Jon Bowden, et al.
BMC Infectious Diseases|January 17, 2023
Real-time analysis of hospital length of stay in a mixed SARS-CoV-2 Omicron and Delta epidemic in New South Wales, AustraliaRuarai J Tobin, James G Wood, Duleepa Jayasundara, et al.
Blood|December 9, 2004
TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cellsJean-Philippe Herbeuval, Adriano Boasso, Jean-Charles Grivel, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 1990
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytesA Hosmalin, M Clerici, R Houghten, et al.
Pageof 54

Showing results (401-410 of 531) with videos related to

Sort By:
Pageof 54
The Journal of Infectious Diseases|February 1, 1996
Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelopeA Beretta, S H Weiss, G Rappocciolo, et al.
The Journal of Infectious Diseases|August 1, 1994
Demonstration of human T lymphotropic virus type I (HTLV-I)-specific T cell responses from seronegative and polymerase chain reaction-negative persons exposed to HTLV-IM Nishimura, A G Kermode, M Clerici, et al.
Infection Control and Hospital Epidemiology|July 8, 1999
Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workersR D'Amico, L A Pinto, P Meyer, et al.
The Journal of Clinical Investigation|April 1, 1989
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individualsH Golding, G M Shearer, K Hillman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 1994
Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesisM Clerici, A Sarin, R L Coffman, et al.
AIDS (London, England)|January 6, 1999
Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatmentC Chougnet, K R Fowke, B U Mueller, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pulmonary fibroblast activation during <i>Aspergillus fumigatus</i> infection enhances lung defense via immunomodulation and tissue remodelingJosé P Guirao-Abad, Shannon M Shearer, Jon Bowden, et al.
BMC Infectious Diseases|January 17, 2023
Real-time analysis of hospital length of stay in a mixed SARS-CoV-2 Omicron and Delta epidemic in New South Wales, AustraliaRuarai J Tobin, James G Wood, Duleepa Jayasundara, et al.
Blood|December 9, 2004
TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cellsJean-Philippe Herbeuval, Adriano Boasso, Jean-Charles Grivel, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 1990
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytesA Hosmalin, M Clerici, R Houghten, et al.
Pageof 54